10-K: Nika Pharmaceuticals Reports Increased Net Loss in 2024 Amidst Strategic Business Changes

Nika Pharmaceuticals' 2024 Form 10-K reveals a net loss increase to $95,792, alongside strategic shifts including a common control merger and OTCQB uplisting.

Summary

• Nika Pharmaceuticals, Inc. filed its Form 10-K for the fiscal year ended December 31, 2024.
• The company reported a net loss of $95,792 for 2024, compared to a net loss of $64,833 in 2023.
• General and administrative expenses decreased to $35,174 in 2024 from $64,833 in 2023.
• Professional fees increased to $60,618 in 2024 from $0 in 2023.
• The company's common stock was uplisted to OTCQB on December 9, 2024.
• A common control merger with Nika BioTechnology, Inc. was completed, resulting in the company acquiring an 80% controlling interest in Nika Europe, Ltd.
• The company issued 145,584,500 shares of common stock related to the merger.
• The company's auditors have expressed a 'going concern' opinion due to an accumulated deficit of $8,927,612 and a negative working capital of $221,230.
• Management plans to seek additional debt and/or equity financing to sustain operations.
• As of March 10, 2025, the total outstanding common stock are 1,026,371,000.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the increased net loss, going concern qualification, and internal control weaknesses, but is balanced by the OTCQB uplisting and strategic merger.

Positives

• The company's common stock was uplisted to OTCQB on December 9, 2024, potentially increasing visibility and investor interest.
• The merger with Nika BioTechnology, Inc. resulted in the acquisition of an 80% controlling interest in Nika Europe, Ltd., providing a foothold in European, Asian, and African markets.
• General and administrative expenses decreased to $35,174 in 2024 from $64,833 in 2023.

Negatives

• The company reported a net loss of $95,792 for the year ended December 31, 2024, an increase from the $64,833 loss in 2023.
• The company's auditors have raised concerns about its ability to continue as a going concern due to an accumulated deficit of $8,927,612 and a negative working capital of $221,230.
• The company has not yet generated sustained profits from its operations.
• The company's disclosure controls and procedures were deemed ineffective as of December 31, 2024.
• The company lacks an audit committee and segregation of duties, representing material weaknesses in internal control.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving profitable operations.
• The company faces risks related to changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, and competition.
• The company's lack of cybersecurity processes could pose a risk, although currently considered immaterial.
• The company's internal control weaknesses could adversely affect its ability to accurately report financial data.
• The company is dependent on related party loans to fund operations.

Future Outlook

Management believes the Company will continue to incur losses and negative cash flows from operating activities for the foreseeable future and will need additional equity or debt financing to sustain its operations until it can achieve profitability and positive cash flows, if ever.

Management Comments

• Management plans to seek additional debt and/or equity financing for the Company but cannot assure that such financing will be available on acceptable terms.
• Our current management has agreed to advance funds to the Company on an as needed basis.

Industry Context

Nika Pharmaceuticals is operating in the competitive pharmaceutical and biotechnology industries, requiring significant capital investment for research, development, and regulatory approvals. The company's focus on acquiring rights to manufacture and distribute existing products, as well as developing new ones, reflects a common strategy among smaller pharmaceutical companies to build a product pipeline and generate revenue.

Comparison to Industry Standards

• Comparing Nika Pharmaceuticals to established pharmaceutical companies is difficult due to its early stage and limited revenue.
• Many small biotech companies rely on venture capital or strategic partnerships for funding, similar to Nika's reliance on related party loans.
• The 'going concern' qualification is not uncommon for early-stage biotech companies that are pre-revenue or have limited operating history.
• Comparable companies would be other small OTC-listed pharmaceutical firms with a focus on acquiring and developing niche products.

Related Party Transactions

• During the year ended December 31, 2024 and 2023, Dimitar Slavchev Savov, CEO, advanced the Company $103,419 and $83,565, respectively, to pay for general operating expenses.
• During the year ended December 31, 2024, Nika Pharmaceuticals LTD, advanced the Company $34,000, to pay for general operating expenses.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional equity financing.
• Employees' job security is dependent on the company's ability to secure funding and achieve profitability.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company plans to seek additional debt and/or equity financing.
• The company intends to rely on exemptions from certain disclosure requirements as an emerging growth company.
• The company intends to recruit additional professionals to improve internal controls.

Key Dates

Keywords

Nika Pharmaceuticals, Form 10-K, Financial Results, Merger, OTCQB, Going Concern, Pharmaceuticals, Biotechnology